top of page
Precision Therapies For Myeloid Disorders
in Inflammation & Immunology
Taran Therapeutics is developing therapies targeting the underlying drivers of myeloid disorders, initially in hematology and oncology, to address critical unmet needs in patient care.
OUR MISSION
Patients First. Urgently.
For patients facing cancers and immune-driven diseases with limited treatment choices, time matters.
We feel this greatly. Taran Therapeutics is working towards advancing targeted, novel therapies where the need is greatest.
OUR FEATURED PROGRAM
LENZ: A Focused Therapy on CMML
Lenzilumab (LENZ) is a first-in-class monoclonal antibody implicated in certain types of leukemia and inflammatory conditions, specifically for Chronic Myelomonocytic Leukemia (CMML). LENZ safely neutralizes the GM-CSF pathway, a pathway that fuels the growth of abnormal cells in CMML. Our therapy attacks one of the main drivers of the disease.
Taran is preparing LENZ for a Phase 3 study to treat Chronic Myelomonocytic Leukemia.
LENZ has the potential to significantly improve outcomes for thousands of CMML patients who are currently reliant on a decades-old standard-of-care therapy that simply isn't working.
Strong Efficacy Signal
Phase 2 response rates are ~80%, including marrow CR, an ~4x improvement vs. SoC
Deep Safety Record
No serious safety issues in 700+ subjects across nine studies
Reduces Transformed Secondary AML
LENZ treatment ~10% vs. ~50% expected
Phase 3 Ready
Estimated 3 year study with potential for early-approval
~50k CMML
patients annually
Addressable patient population
TARAN'S DIVERSE PORTFOLIO
Our science extends across multiple immunologic and inflammatory conditions.
Our secondary program, Ifabotuzumab (IFAB), is an early-stage antibody drug conjugate (ADC) and has already been studied in more than 70 patients across blood cancers and a glioblastoma (brain cancer) trial. We are exploring IFAB's potential in additional solid tumors and fibrotic disease.
bottom of page